Abbott Laboratories ($ABT) Stock Forecast: Up 1.3% Today

What is Abbott Laboratories?

Abbott Laboratories (ABT) is a global healthcare company specializing in medical devices, diagnostics, branded generic medicines, and nutritional products, with a strong presence in various healthcare industry segments.

Why is Abbott Laboratories going up?

ABT stock is up 1.3% on Jan 5, 2026 16:15

• ABT witnessed a significant bullish movement today.
• This trend may be linked to the recent rise in institutional holdings by Asset Management One Co. Ltd., suggesting confidence in the company's performance and future prospects.
• Furthermore, Abbott Laboratories disclosed strong Q3 earnings, increased its quarterly dividend, and garnered a "Moderate Buy" consensus rating from analysts, likely contributing to market optimism and heightened investor interest in the stock.
• The positive institutional investment activity and favorable financial performance indicators have driven ABT's stock price higher today.

ABT Price Chart

ABT Technical Analysis

ABT News

Hologic Trading Near 52-Week High: How Should You Play the Stock?

Hologic's shares closed near their 52-week high, outperforming its industry and sector, driven by strong growth in Molecular Diagnostics, Breast Health, and GYN Surgical divisions, alongside a proposed $18.3 billion take-private deal. Despite macroeconomic headwinds and tariffs, the company's innovation, clinical evidence, and regulatory approvals suggest a "hold" position for current investors due to its favorable price performance and appealing valuation. Prospective buyers are advised to wait for more clarity.

https://finviz.com/news/267052/hologic-trading-near-52-week-high-how-should-you-play-the-stock

The Truth About Medtronic plc: Is This ‘Boring’ Stock Actually a Silent Flex?

Medtronic plc is presented as a medical technology giant that, while not a "meme stock," is a significant player in healthcare. The article explores whether this "boring" stock is a valuable long-term investment, examining its business, market perception, and risks. It concludes that Medtronic is a stable, dividend-paying company suited for core portfolios rather than speculative, high-volatility trading.

https://www.ad-hoc-news.de/boerse/news/ueberblick/the-truth-about-medtronic-plc-is-this-boring-stock-actually-a/68460446

PDX: An 8.6% Yield, 12% Discount, And Potential Recovery In 2026

The PIMCO Dynamic Income Strategy Fund (PDX) offers an 8.64% yield and trades at a -12% discount to NAV, which is rare for PIMCO CEFs. PDX is transitioning from an energy-centric portfolio to a multi-sector credit fund, actively reducing its energy exposure to 25%. While high leverage and concentrated energy positions have historically increased volatility, management's de-risking efforts and potential rate cuts could lead to a recovery in 2026.

https://seekingalpha.com/article/4856740-pdx-8-6-percent-yield-12-percent-discount-potential-recovery-in-2026

Abbott Laboratories $ABT Shares Acquired by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. increased its holdings in Abbott Laboratories (NYSE:ABT) by 2.4% during Q3, now owning 858,834 shares valued at $115.03 million. Other institutional investors also adjusted their positions in ABT, with institutional ownership reaching 75.18%. Abbott Laboratories recently reported strong Q3 earnings, increased its quarterly dividend, and received a "Moderate Buy" consensus rating from analysts with an average target price of $147.00.

https://www.marketbeat.com/instant-alerts/filing-abbott-laboratories-abt-shares-acquired-by-asset-management-one-co-ltd-2026-01-04/

NeoGenomics Adds Diagnostics Executive Jack Kenny To Board

NeoGenomics has appointed John P. "Jack" Kenny, a diagnostics and laboratory services veteran, to its Board of Directors. Kenny brings over 30 years of experience to the role as NeoGenomics aims to expand its oncology testing services, particularly in next-generation sequencing (NGS) and minimal residual disease (MRD) testing. His appointment strengthens the board's expertise in a rapidly evolving field, replacing Alison Hannah, MD, who served for over a decade.

https://pulse2.com/neogenomics-adds-diagnostics-executive-jack-kenny-to-board/

Trending Today

Natural Gas ($GAS) Commodity Forecast: Up 29.2% Today

Ethereum ($ETH) Crypto Forecast: Down 5.1% Today

The Sandbox ($SAND) Crypto Forecast: Up 5.1% Today

TRON ($TRX) Crypto Forecast: Down 5.0% Today

Dash ($DASH) Crypto Forecast: Down 5.7% Today

Monero ($XMR) Crypto Forecast: Down 18.9% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.0% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 5.2% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.8% Today

Illumina Inc. ($ILMN) Stock Forecast: Up 5.2% Today

Abbott Laboratories Price History

16.09.2024 - ABT Stock was down 0.1%

• Despite strong Q3 earnings surpassing expectations, ABT's stock saw a bearish trend today.
• The market reaction may have been influenced by mixed U.S. stock futures trading, impacting investor sentiment towards healthcare stocks like ABT.
• Today’s 2.26% decline in stock price could be due to profit-taking by investors following a period of consistent growth.
• While ABT remains on track to meet its annual forecast, short-term market movements and overall market conditions likely played a role in today's bearish performance.

02.04.2025 - ABT Stock was up 2.8%

• ABT's stock price surged by 0.40% during the current market session, signaling strong bullish momentum.
• Despite a minor decline in the last month, the stock has notably jumped by 22.07% over the past year, reflecting promising long-term growth prospects.
• The optimistic momentum can be attributed to favorable market conditions, potential advancements in the healthcare industry, or a positive earnings outlook for the company.

05.00.2026 - ABT Stock was up 1.3%

• ABT witnessed a significant bullish movement today.
• This trend may be linked to the recent rise in institutional holdings by Asset Management One Co. Ltd., suggesting confidence in the company's performance and future prospects.
• Furthermore, Abbott Laboratories disclosed strong Q3 earnings, increased its quarterly dividend, and garnered a "Moderate Buy" consensus rating from analysts, likely contributing to market optimism and heightened investor interest in the stock.
• The positive institutional investment activity and favorable financial performance indicators have driven ABT's stock price higher today.

07.05.2024 - ABT Stock was up 1.3%

• ABT stock experienced a bullish movement today, likely driven by multiple factors:
• The positive outlook on dividend-paying companies in the current market environment could have attracted investors to ABT due to its strong dividend track record.
• The average brokerage recommendation of 1.50 for ABT, indicating a Strong Buy sentiment from analysts, might have boosted investor confidence in the stock.
• The technical issues leading to trading halts for NYSE stocks, including ABT, could have created volatility in the market, potentially leading to increased trading activity in ABT as investors sought stability in healthcare stocks.
• Overall, the combination of positive market sentiment towards dividend stocks, favorable analyst recommendations, and technical issues impacting trading on the NYSE likely contributed to ABT's bullish movement today.

17.06.2025 - ABT Stock was down 8.0%

• ABT stock faced a notable decline today, with a decrease of 8.07%.
• The company's third-quarter earnings projection, which fell below analyst expectations, is believed to have played a role in the significant drop in the stock price.
• Investors' reaction to the adjusted earnings outlook likely triggered a sell-off of ABT shares during the pre-market trading session.
• Heightened market sensitivity ahead of the upcoming second-quarter earnings release may have prompted investors to reposition themselves based on the revised forecasts.

16.03.2025 - ABT Stock was up 5.4%

• Abbott Laboratories reported positive Q1 earnings, with sales increasing by 7.2% and adjusted EPS surpassing consensus estimates, potentially influencing the uptick in ABT stock.
• The company's strong performance in the Medical Device segment, notably with products like FreeStyle Libre and heart-related devices, demonstrated its resilience in uncertain times and its ability to drive growth.
• The purchase of a substantial amount of ABT stock by a member of the House of Representatives might have boosted investor confidence in the company's future, leading to increased buying activity and pushing the stock price up.
• Despite the overall market decline witnessed today, Abbott Laboratories' robust financial results, favorable market sentiment, and strategic growth initiatives likely propelled the bullish trend in ABT stock.

11.09.2023 - ABT Stock was down 5.2%

• The bearish movement in ABT's stock today could be attributed to the following factors:
• 1. Market shift: Abbott Laboratories is exploring the consumer wearables market as COVID testing sales dwindle. This strategic move might have raised concerns among investors about the company's focus and potential impact on its financial performance.
• 2. Elon Musk's influence: Jim Cramer mentioned on CNBC's "Mad Money" that he is a seller of ABT because Elon Musk stated that he doesn't like that business. Musk's negative sentiment towards the company could have influenced investor sentiment and contributed to the bearish movement.
• 3. Stake increase: Moody Lynn & Lieberson LLC increased its stake in Abbott Laboratories, indicating confidence in the company. However, this positive development might not have been enough to counterbalance other factors affecting the stock's movement.
• 4. Overall market conditions: The bearish movement in ABT's stock could also be a result of broader market trends or sector-specific factors impacting healthcare stocks. It's important to consider the overall market conditions when assessing individual stock movements.

20.01.2024 - ABT Stock was up 1.9%

• Several factors may have contributed to the bullish movement in ABT stock:
• Abbott Laboratories announced a $0.55 dividend, which could have attracted income-seeking investors, thereby increasing the stock's appeal.
• The FDA's Circulatory System Devices Panel provided a favorable recommendation for Abbott's Minimally Invasive Heart Valve Repair Device, the TriClip system, potentially boosting investor confidence in the company's medical innovations.
• An FDA independent panel endorsed the safety profile of Abbott's heart device TriClip, showcasing the company's dedication to pioneering healthcare solutions. This news likely fueled investor confidence and drove the stock price up.

15.02.2024 - ABT Stock was down 5.4%

• ABT stock experienced a bearish trend today possibly due to profit-taking by investors following a period of strong performance.
• Analysts have pointed to discussions on growth in the in-vitro diagnostics market and Roche's AI-based glucose monitoring system launch as factors diverting attention from ABT momentarily.
• The overall optimism in the healthcare industry, exemplified by the Medical Devices ETF reaching a 52-week peak, may have prompted some investors to adjust their portfolios within the sector, impacting ABT's stock performance.
• ABT's sustained outperformance over time, as alluded to by market observations, suggests that today's bearish movement could be a brief correction in the context of the company's favorable long-term trajectory.

15.09.2025 - ABT Stock was down 4.8%

• The stock of Abbott Laboratories (ABT) faced a downward trend in the market today.
• Negative market reaction followed the company's third-quarter sales, which were slightly below anticipated levels.
• Abbott Laboratories' revised fiscal 2025 guidance also played a role in driving down the stock price.
• Despite predictions of increased earnings per share for the third quarter, investor focus on sales performance and future prospects led to the bearish movement in the stock.

18.06.2024 - ABT Stock was down 1.2%

• Despite reporting strong Q2 earnings with EPS beating estimates, Abbott Laboratories (ABT) experienced a bearish movement in its stock.
• The market may have reacted negatively to a slight revenue miss, even though the full-year guidance was raised, indicating potential concerns about future performance.
• Investors might have been expecting higher revenue growth, leading to profit-taking and a bearish trend in the stock price.
• Market sentiment could have been influenced by broader economic conditions or global events, overshadowing the positive earnings beat.

17.06.2025 - ABT Stock was down 6.3%

• A weak earnings projection for the third quarter by Abbott Laboratories, falling below market expectations, caused a significant drop in the stock's value.
• Analysts, who had adjusted their predictions prior to the earnings announcement, were anticipating an uptick in quarterly earnings per share. The unexpected weaker guidance likely surprised investors, contributing to the bearish trend.
• The general pessimism towards ABT was magnified by the overall downtrend in U.S. stock futures, with the Dow futures declining by around 0.2% on the same day.